Accessibility Statement
Skip to main content
Sustainability
Subsidiaries
Partners
Careers
Investors
Contact
Globe
Lilly
Menu
Menu
Menu closed
Lilly
Close
Close
Company
Expand mega menu
Expand submenu
Collapse Company
Company
WHO WE ARE
Expand
About Lilly
Key Facts
Recognitions
Powered by Purpose
LEADERSHIP
Expand
Governance
Executive Committee
Board of Directors
POLICIES & REPORTS
Expand
Public Policy
Annual Report & Proxy Statement
Year in Review
Science
Expand mega menu
Expand submenu
Collapse Science
Science
DISCOVERY
Expand
Clinical Development Pipeline
Research & Scientific Discovery
Principles of Medical Research
100 Years of Insulin
DISEASE AREAS
Expand
Alzheimer's
Cancer
Diabetes
Immunology
Obesity
Pain
CLINICAL RESEARCH
Expand
Clinical Trials
Diversity in Clinical Trials
Lilly Trials
Expanded Access
CSR Synopses
PARTNERS
Expand
Collaborate With Us
Scientific Areas of Interest
Office of Alliance Management
Lilly Research Award Program
Medicines
Expand mega menu
Expand submenu
Collapse Medicines
Medicines
SAFETY
Expand
Patient Safety
Medication Safety
Manufacturing & Quality
OUR MEDICINES
Expand
Current Medicines
Historic Medicines
Suggestions for Patients
RESOURCES
Expand
Lilly Insulin Access Programs
LillyDirect
Lilly Insulin State Patient Assistance Programs
Lilly Oncology Support Center
Lilly Pricing Information
The Lilly Answers Center
Lilly Cares Foundation
Impact
Expand mega menu
Expand submenu
Collapse Impact
Impact
OUR IMPACT
Expand
Overview
Lilly Foundation
Lilly Grant Office
IMPACT AREAS
Expand
Increase Access to Medicines
Improve Lives and Communities
Empower a Diverse Workforce
Minimize Our Environmental Impact
Operate Ethically and Responsibly
TRANSPARENCY
Expand
Sustainability Report
State-Specific Requirements
News
Expand mega menu
Expand submenu
Collapse News
News
STORIES
Expand
Caring
Science
Policy
All Stories
PRESS RELEASES
Expand
Recent
Archives
MEDIA
Expand
All News
Media Kits
Media Contacts
Social Media Guidelines
Search
Sustainability
Subsidiaries
Partners
Careers
Investors
Contact
Globe
Sitemap
Avid
Diversity in Clinical Trials
Driving Clinical Trial Innovation (MRU)
Contact Us
Designated Alternate Contacts for Reporting Concerns (for Countries That Limit Hotline Reporting)
100 Years of Insulin
Research & Scientific Discovery
Disarm Therapeutics
Alzheimer's
COVID-19 Antibody Allocation & Transparency
Diabetes
Diabetes Resources for College Students
Immunology
Atopic Dermatitis
Ulcerative Colitis
Obesity
Employer Benefit Design
Increase Access To Medicines
Empower a Diverse Workforce
Improve Lives and Communities
Minimize Our Environmental Impact
Operate Ethically and Responsibly
Ethical Conduct for Financial Management
Our Impact
Our Racial Justice Commitment: From Pledge to Progress
Homepage - Masterbrand - Current
Gabrielle Sulzberger
Kimberly H. Johnson
Mary Lynne Hedley, Ph.D.
Alonzo Weems
Anat Ashkenazi
Diogo Rau
Edgardo Hernandez
Eric Dozier
Ilya Yuffa
Jacob Van Naarden
Lilly Corporate Social Media Guidelines
.Lilly Global Top Level Domain - DO NOT DELETE
Sitemap
Connecting to Lilly
Media Downloads
All News
News
Media Contacts
Media Kits
Showcasing New Data at the American Diabetes Association's 83rd Scientific Sessions
Baricitinib for COVID-19
Insulin Affordability Media Kit
Jaypirca® (pirtobrutinib): First and Only Non-Covalent (Reversible) BTK Inhibitor Approved by the U.S. FDA for CLL or SLL Patients Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
Lyumjev® (insulin lispro-aabc) Injection Approved by U.S. FDA for Children with Diabetes
Monoclonal Antibody Assets for Social Media Distribution
Mounjaro® (tirzepatide) Injection: The First and Only GIP and GLP-1 Receptor Agonist Approved for Type 2 Diabetes
Retevmo® (selpercatinib): Approved by the U.S. FDA as the First Therapy Specifically for Patients with Advanced RET-Driven Cancers
Lilly to Begin Rollout of Tempo™ Personalized Diabetes Management Platform
Verzenio® (abemaciclib): Expanded Indication Approved by the U.S. FDA for Treatment of High-Risk Early Breast Cancer
Zepbound™
Press Releases
Stories
Obesity Care is Health Care
Update on Humalog® (insulin lispro injection) and Insulin Lispro Injection 10mL Vial
Manufacturing & Quality
European Union and United Kingdom Declarations
Product Cybersecurity Coordinated Vulnerability Disclosure Policy
Savings Card Help
Partners - Smart Risks. Bold Science.
Lilly Catalyze360
Connect with Us | Partnering
Partnering Events and Conferences
2021 Year in Review
2022 Year in Review
2023 Year in Review
Public Policy Engagement and Political Participation
Privacy Statement
Lilly Colorado Insulin State Patient Assistance Program™
Insulin for $35 or Less a Month - Insulin Affordability
Lilly Insulin State Patient Assistance Programs
Lilly Pricing Information
LillyDirect™
Lilly Maine Insulin State Patient Assistance Program™
Lilly Minnesota Insulin State Patient Assistance Program™
Subsidiaries
Sigilon Therapeutics
Versanis
Versanis Privacy Trials
Suppliers
Accounts Payable
Invoicing
POTerms and Conditions
Lilly Third Party Provider Privacy Notice
Contacting Accounts Payable
New Supplier Onboarding and Supplier Information
Payments
Lilly Supplier Ariba Portal
Prospective Suppliers
Supplier Diversity
Supplier Resources
Pharmaceutical Marketer Price Disclosure Law: Vermont
Olympics - Team USA Partnership
About Lilly
Position Statements
Powered by Purpose
Lilly Supplier eConnect Portal
Your Story Matters - User Generated Content